Establishment profile
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Rd, TARRYTOWN, NY, 10591
Operated by REGENERON PHARMACEUTICALS, INC · 1 of 2 establishments
325412 — Pharmaceutical Preparation Manufacturing
EIN 133444607
Summary
Regeneron Pharmaceuticals, Inc. has no OSHA inspection history on file. Federal records covering wage, environmental, labor relations, and other agencies are noted below where present.
The most recent federal enforcement activity was recorded 0 days ago.
Federal records were found in 1 of 15 sources. Sources without matching records returned empty for this establishment.
Agency coverage
Regeneron Pharmaceuticals, Inc. appears in EPA environmental compliance, OFLC visa and labor certification (historical), and FMCSA motor carrier registration records only. No matching records were found in OSHA workplace safety, WHD wage enforcement, MSHA mine safety, NLRB labor relations, SAM.gov federal debarment, CMS nursing home enforcement, UVA Corporate Prosecution Registry, CPSC product recalls, or NHTSA vehicle recalls.
OSHA workplace safety
No OSHA inspections, citations, or accidents on file for Regeneron Pharmaceuticals, Inc.. Verify directly with Occupational Safety and Health Administration →
Safety self-report (OSHA 300A)
Recordable injury rates the employer filed with OSHA’s Injury Tracking Application. DART covers cases with days away, restricted, or transferred; TRIR is the total recordable case rate.
Reported for 3,925 average annual employees at this establishment.
Source: OSHA ITA Form 300A (employer self-reported). Rates are per 100 full-time equivalent workers. Establishments below the ~10-FTE threshold are not required to report.
Industry benchmark
BLS rates reflect industry-wide averages. Self-reported figures come from OSHA’s Injury Tracking Application; absence of self-reported data does not necessarily indicate non-compliance — many establishments fall below the ITA reporting threshold.
OSHA severe injury reports
Self-reported events under 29 CFR 1904.39 (24-hour notification of hospitalization, amputation, or loss of an eye) · Jan 2023 – Apr 2025
Most frequent event: Fall on same level due to slipping
Source: OSHA Severe Injury Reports (federal OSHA only; state-plan states like California, Oregon, and Washington maintain their own programs and do not consistently report into this feed).
Severe injury reports — events
Each row is a hospitalization, amputation, or eye-loss event the employer self-reported to OSHA under 29 CFR 1904.39. Narratives are written by the reporting employer.
| Date | Event | Body part | Outcome | |
|---|---|---|---|---|
| Apr 4, 2025 | Non-venomous animal bites except "bugs" | Hand(s), finger(s) unspecified | Hospitalized | |
| Jan 19, 2023 | Fall on same level due to slipping | Knee(s) | Hospitalized | |
| Jan 11, 2023 | Fall while sitting | Brain | Hospitalized |
Source: OSHA Severe Injury Reports. Federal-OSHA jurisdiction only by default; some state-plan programs report voluntarily.
Activity timeline
Most recent federal enforcement activity recorded 0 days ago. Data on this page is refreshed weekly.
Wage & Hour Division (WHD)
No WHD wage, overtime, or child-labor enforcement cases on file for Regeneron Pharmaceuticals, Inc.. Verify directly with Wage and Hour Division →
Mine safety (MSHA)
No MSHA mine safety violations on file for Regeneron Pharmaceuticals, Inc.. Verify directly with Mine Safety and Health Administration →
Labor relations (NLRB)
No NLRB unfair labor practice charges or union representation cases on file for Regeneron Pharmaceuticals, Inc.. Verify directly with National Labor Relations Board →
Visa & labor certification (OFLC) — historical
Office of Foreign Labor Certification — labor condition applications for H-1B, H-2A, H-2B visa programs. Wage ratio = offered / prevailing wage. Historical data only: DOL ended OFLC Performance Data Disclosure publication in 2026, so the figures above reflect filings through the last ingested cycle and are not being refreshed. Treat as a historical snapshot, not a current signal.
Environmental compliance (EPA)
EPA Enforcement and Compliance History — Clean Air Act, Clean Water Act, RCRA, Safe Drinking Water Act. Status: No Violation Identified.
EPA-registered facilities
Every EPA ECHO facility associated with this employer, sorted most-significant first. Each row links to EPA’s Detailed Facility Report for the source-of-truth record. Permits column lists active programs (Air = Clean Air Act, Water = Clean Water Act, RCRA = hazardous waste, TRI = Toxics Release Inventory reporting). 1 facility.
| Facility | Permits | Status | Inspections | Formal actions | Penalties | Last inspected | ECHO |
|---|---|---|---|---|---|---|---|
REGENERON PHARMACEUTICALS INC 777 OLD SAW MILL RIVER RD · TARRYTOWN, NY, 10591 | RCRA | No Violation Identified QNCR 2 | 1 | 0 | — | Sep 2025 | View → |
Source: EPA ECHO (Enforcement and Compliance History Online). Compliance status follows EPA’s own labels (“Sig Violation” = significant noncompliance; QNCR = quarters of noncompliance over the recent reporting window). Inactive facilities (struck through) retain historical enforcement records even after operations ceased.
Motor carrier safety (FMCSA)
Federal Motor Carrier Safety Administration — DOT-regulated carrier registration and fleet data.
Federal criminal prosecution record
No federal criminal prosecutions, plea agreements, or deferred-prosecution agreements on file for Regeneron Pharmaceuticals, Inc.. Verify directly with UVA Corporate Prosecution Registry →
Federal contracts
This location
- Department of DefensePRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19): IN SUPPORT OF OPERATION WARP SPEED (OWS), THE GOVERNMENT IS PURCHASING UP TO 1,250,000 DOSES OF THE EMERGENCY USE AUTHORIZATION (EUA) THERAPEUTIC.contract · Last action 2022-07-29$5,565,000,000
- Department of Health and Human ServicesIGF::OT::IGFcontract · Last action 2025-08-06$693,056,927
- Department of Health and Human ServicesIGF::OT::IGF - REGENERON OTHER TRANSACTION AUTHORITY (OTA) AWARDcontract · Last action 2025-08-08$279,610,568
- Department of Health and Human ServicesREGENERON-ANTI-EBOLA ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT IGF::OT::IGFcontract · Last action 2024-07-23$33,135,560
- Department of Health and Human ServicesIGF::OT::IGFcontract · Last action 2026-03-19$8,601,629
- Department of Veterans AffairsEVKEEZA DRUGcontract · Last action 2021-11-24$494,095
- Department of Veterans AffairsEVKEEZAcontract · Last action 2021-09-08$148,229
- Department of Health and Human ServicesASD SPECIALTY HEALTHCARE INC:1107102 [13-016790]- ACCOUNT #71740contract · Last action 2013-09-27$14,131
- Department of Veterans Affairs65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARDcontract · Last action 2026-03-26$0
- Department of Veterans AffairsBPA FOR EVKEEZA.contract · Last action 2025-11-13$0
- Department of Veterans AffairsBPA FOR ARCALYST AND EVKEEZA BASE YEAR PLUS FOUR ONE-YEAR OPTION PERIODScontract · Last action 2021-09-13$0
- Department of Veterans Affairs65IB PHARMACEUTICALScontract · Last action 2021-05-20$0
- Department of Veterans AffairsSPECIALTY BPA - ARCALYSTcontract · Last action 2019-12-31$0
- Department of Veterans AffairsFSC GROUP 65 PART I.SECTION B DRUG,PHARMACEUTICALS & HEMATOLOGY RELATED PRODUCTScontract · Last action 2015-07-10$0
- Department of Veterans AffairsSPECIALTY BPA - ARCALYSTcontract · Last action 2014-12-22$0
- Department of Veterans AffairsFSC GROUP 65 PART I,SECTION B-DRUGS,PHARMAEUTICALS & HEMATOLOGY REALTED PRODUCTScontract · Last action 2008-09-18$0
Federal contract dollars to this establishment. Primary NAICS: 325414 - BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING. Last action: 2026-03-26. Source: USAspending.gov, net obligations. Recipient address is the SAM registration / HQ address, not necessarily the worksite.
In the news
Part of a larger organization
Regeneron Pharmaceuticals, Inc. is one of 2 establishments rolled up under the parent organization REGENERON PHARMACEUTICALS, INC.
Federal enforcement records on this page represent activity at this specific establishment only. The full enforcement footprint of REGENERON PHARMACEUTICALS, INC across all 2 of its tracked locations is viewable on the parent profile.
Other employers in this industry and state
Other employers in pharmaceutical preparation manufacturing within NY, ordered by federal enforcement volume:
- TOPIDERM INCAMITYVILLE — 4 federal enforcement records
- Time-Cap LabsFarmingdale — 3 federal enforcement records
- FRESENIUS KABI USA LLCGRAND ISLAND — 2 federal enforcement records
- CONTRACT PHARMACAL CORPORATIONHAUPPAUGE — 2 federal enforcement records
- LNK INTERNATIONAL, INC.HAUPPAUGE — 2 federal enforcement records
- UCB MANUFACTURING, INC.ROCHESTER — 2 federal enforcement records
- INVAGEN PHARMACEUTICALS, INC.HAUPPAUGE — 2 federal enforcement records
- MALLINCKRODT INC.HOBART — 2 federal enforcement records
- KABCO PHARMACEUTICALS, INC.AMITYVILLE — 2 federal enforcement records
- BACTOLAC PHARMACEUTICAL, INC.HAUPPAUGE — 2 federal enforcement records
Other locations under this parent
Other establishments operated by REGENERON PHARMACEUTICALS, INC, ordered by federal enforcement volume:
- REGENERON PHARMACEUTICALS INC.RENSSELAER, NY — 1 federal enforcement record
Related searches
- All REGENERON PHARMACEUTICALS, INC locationsParent rollup
- Pharmaceutical Preparation ManufacturingAll employers in this industry
- Employers in NYState-wide enforcement data
- Pharmaceutical Preparation Manufacturing in NYIndustry × state cross-filter
About this data
This profile aggregates federal enforcement records on Regeneron Pharmaceuticals, Inc. from every major federal compliance and enforcement source plus the UVA Corporate Prosecution Registry. OSHA workplace safety inspections, WHD wage cases, MSHA mine safety, EPA environmental enforcement, NLRB labor relations, OFLC visa/labor certification, FMCSA motor carrier registration, SAM.gov debarments, CMS nursing-home records, BLS industry safety benchmarks, OSHA ITA self-reported injury rates, SEC enforcement and financial disclosures, CPSC and NHTSA recalls.
Establishments are matched across agencies using normalized employer name, state, and ZIP code. This establishment resolves to the parent rollup REGENERON PHARMACEUTICALS, INC, which operates 2 establishments in our dataset.
OSHA citations typically appear 3–8 months after the inspection, so very recent enforcement actions may not yet be reflected. Profiles may be incomplete if the establishment operates under multiple legal names or files under variations our entity-matching rules don’t yet cover. To report a missing record or correction, email corrections@fastdol.com.
Need API access, bulk download, or licensed redistribution? The website is free. Programmatic and licensed access is handled separately.
Contact sales →Frequently asked
- What is Regeneron Pharmaceuticals, Inc.'s OSHA violation history?
- Regeneron Pharmaceuticals, Inc. has no OSHA inspections on record.
- How does Regeneron Pharmaceuticals, Inc.'s safety record compare to its industry?
- Regeneron Pharmaceuticals, Inc. operates in the pharmaceutical preparation manufacturing industry. The industry average Total Recordable Incident Rate (TRIR) is 1.4. Regeneron Pharmaceuticals, Inc.'s self-reported DART rate is 0.52 compared to an industry average of 0.9.